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Abstract 
Purpose: To evaluate the application of apparent diffusion coefficient (ADC) values derived from 
diffusion-weighted imaging (DWI) using single-slice histogram analysis to study the chemotherapy 
responses in lung cancer.  
Methods: A total of 22 chemotherapy patients with advanced lung cancer from the Nanjing Drum Tower 
Hospital (Nanjing, China) were included in the study. We obtained DWI before and during 
chemotherapy, performed single-slice histogram analysis of ADC values, and assessed responses after 
3 months of chemotherapy. Differences in ADC histogram parameters were compared between the 
responder and non-responder groups.  
Results: After therapy, we classified 13 as responders and 9 patients as non-responders. The recorded 
peak ADC value (ADCpeak) and lowest ADC value (ADClowest) did not show any significant difference in 
baseline ADClowest and ADCpeak between responders and non-responders. After chemotherapy, 13 
responders had significant increase in ADClowest and ADCpeak compared with pre-treatment values (p < 
0.001). ADClowest significantly increased in 9 non-responders (p < 0.05), although ADCpeak did not 
significantly increase. ADCpeak changes were significantly larger in the responder group than in the non-
responder group (p = 0.024). ADClowest changes after treatment were larger in the responder group than 
in the non-responder group, though not significantly.  
Conclusion: ADC values derived from single-slice histogram analysis may provide a useful and 
clinically feasible method for monitoring early chemotherapy response in patients with lung cancer. 
 
Keywords: Lung cancer, Chemotherapy, Apparent diffusion coefficient values, Diffusion-weighted 
imaging, Single-slice histogram analysis 
 
This is an Open Access article that uses a funding model which does not charge readers or their institutions 
for access and distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly credited. 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Chemotherapy is the dominant treatment 
strategy for patients with advanced lung cancer. 
Response Evaluation Criteria in Solid Tumors 
(RECIST) is often used as standard for 
evaluating treatment responses in lung cancer, 
which analyzes tumor size changes by 
-----------------------------------------------------------------------------------------------------------------------------------------------------
© 2018  The authors. This work is licensed under the Creative Commons Attribution 4.0 International License 
 
 
Xu et al 
682 
 
employing computed tomography (CT) [1]. 
However, because of the relatively slow tumor 
shrinkage, the first response evaluation is often 
carried out after two cycles of chemotherapy by 
CT [2], conventional imaging procedures may not 
accurately assess the response at the early 
treatment stage.  
 
In recent years, investigations have reported that 
diffusion-weighted imaging (DWI) has potential 
for monitoring the early treatment response in 
many malignant tumors, including rectal cancer, 
cervical cancer, breast cancer, head and neck 
cancers, prostate cancer and brain tumors [3 - 5], 
and ADC derived from DWI changes as early as 
24 h after therapy [6]. A variety of methods have 
been applied to measuring mean ADC values on 
ADC maps from various regions of interest 
(ROIs) located in the tumor [7,8]. Histogram 
analysis based on the whole-tumor ROI method 
is preferred for differentiating or grading tumors 
or predicting treatment response in various 
organs [9-12]. Single-slice histogram analysis 
can be used to generate the ADC histogram, 
which represents the pixel frequency of each 
ADC value for the slice image. Single-slice 
histogram analysis requires virtually no data 
manipulation and can be generated in seconds.  
 
The goal of the present study is to analyze ADC 
values derived from DWI using single-slice 
histogram analysis, andalso to investigate the 
usefulness of ADC values in evaluating the 






This study was approved by the Ethical 
Committee of Nanjing Drum Tower Hospital, 
Nanjing, China (approval no. EH201501-3), and 
was performed according to the guidelines of 
Declaration of Helsinki [13]. All patients were 
informed about the potential contraindications 
and benefits associated with DWI and contrast-
enhanced magnetic resonance imaging (MRI).  
 
Patients in this study were diagnosed with stage 
IIIB or IV histologically confirmed advanced lung 
cancer at Nanjing Drum Tower Hospital (Nanjing, 
China) from Feb. 2015 to Aug. 2016 and met the 
following inclusion criteria: the largest diameter of 
the pulmonary mass was 3.0 cm or larger, no 
history of previous chemotherapy or radiation 
therapy, and no contraindication to high-field 
strength MRI (no claustrophobia and no known 
metallic implants). Lung cancer in all patients 
was pathologically confirmed by bronchoscopic 
biopsy or percutaneous lung biopsy. The 
histological types of cancer in patients included 
adenocarcinomas, small cell carcinoma and 
squamous cell carcinoma. The exclusion criteria 
included: having contraindication to 
gadopentetate dimeglumine (allergy or renal 
dysfunction), undergoing radiotherapy 
simultaneously with chemotherapy, interruption 
of treatment in 3 months, and poor visualization 
of the tumor by MRI. Tumor response after 3 
months of therapy was evaluated according to 
the RECIST criteria2, including target and non-
target lesions at CT. Tumor response after 
therapy was classified as follows: responders — 
when the target lesion disappeared or when the 
longest diameter of the target lesion decreased 
by at least 30 % from the pre-therapy size; and 
non-responders — when the target lesion was 





Pre-treatment MRIs and post-treatment MRIs 
were obtained within 1 week prior to the first 
course of chemotherapy and 2 weeks after the 
start of the first course of chemotherapy, 
respectively. MRI was carried out by a 1.5-T unit 
with a body phased array coil (Avanto, Siemens, 
Germany). Firstly, breath-hold T2-weighted 
coronal images and T1- and T2-weighted axial 
images were obtained. Subsequently, breath-free 
DWI was obtained in the transverse plane using 
single-shot, spin-echo echo-planar imaging 
sequence with b values of 50 and 800 s/mm2. By 
using the indicated b values above, ADC maps 
were obtained from DWI. The total acquisition 
time for DWI was 50 s. After DWI, the contrast-
enhanced T1-weighted images were performed 
in the axial plane following administration of Gd-




Generation and analysis of single-slice ADC 
histogram. A free-standing workstation (UNITED 
IMAGING Medical Systems) was used and 
single-slice ADC histograms were obtained by 
using the FuncTool of the workstation. The single 
axial slice was selected according to the level of 
the largest diameter of the tumor. Tumor 
boundaries were defined in reference to the T2-
weighted and contrast-enhanced T1-weighted 
images. The ROIs were slightly smaller than 
actual tumor size to reduce the influence of 
partial volume effect. The peak ADC value 
(ADCpeak) and lowest ADC value (ADClowest) of 
the histograms were recorded. The peak value 
for each case was recorded as the ADCpeak and 
the left leading edge of the histogram (where the 
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voxel frequency was approximately 5 pixels) was 




SPSS software version 13.0 (SPSS Inc., 
Chicago, IL, USA) was used for data analysis. 
Paired t-tests were used to compare differences 
between pre- and post-treatment MRI 
parameters in the same patient. Independent 
samples t-tests were performed to compare the 
differences between responders and non-





Among 25 patients, the DWI of 22 (88 %) was 
graded as good or moderate. The DWI of the 
other three patients (12 %) was graded as poor 
and they were excluded from this study. All 22 
patients with qualified baseline DWI received 
chemotherapy. Response assessment after 3 
months of therapy was successfully performed. 
As a result, 13 and 9 patients were classified 
after therapy as responders and non-responders, 
respectively.  
 
Single-slice ADC histograms were generated and 
ADCpeak and ADClowest were recorded from pre-
treatment and post-treatment ADC maps. 
Results and comparisons of ADClowest and 
ADCpeak are shown in Table 1 and Table 2. 
 
Table 1: Lowest ADC values before and after 
chemotherapy 
 


















Values listed are the mean ± standard deviations; 
units, ×10−3 mm2/s. 
 

























Values listed are the mean ± standard deviations; 
units ×10−3 mm2/s 
 
No significant difference was observed in pre-
treatment ADClowest and ADCpeak between 
responders and non-responders (p = 0.855 and p 
= 0.606, respectively).  
 
After chemotherapy, 13 responders had 
significant increases in ADClowest and ADCpeak 
compared with pre-treatment value (p < 0.001). 
Nine non-responders had a significant increase 
in ADClowest (p < 0.05), while there was no 
significant increase in ADCpeak (p > 0.05). 
Changes in ADCpeak were more significant in the 
responder group than in the non-responder 
group (p = 0.024). Although no statistically 
changes in ADClowest were larger in the 
responder group than that in non-responder 




Histogram analysis is usually used to analyze 
pixel numbers with the same signal intensity in 
an ROI, evaluate the distributions of tumor signal 
intensity, and describe the heterogeneity of the 
tumor. In particular, histogram analysis for the 
whole tumor can reduce the arbitrariness that 
can occur with drawing ROIs. Hence, ADC 
histogram analysis has been considered to be a 
more reproducible method to determine tumor 
heterogeneity, which is significant because 
heterogeneity is associated with poorer 
prognosis [15,16].  
 
The tumor heterogeneity change can be 
analyzed intuitively by histogram and 
quantitatively by descriptive parameters of the 
histogram [17]. However, the major problem in 
ROI drawing for the whole lesion may be the 
irregular shape of lung cancer. Histogram 
analysis of the whole lung cancer lesionis labor-
intensive and requires professional software that 
is not commonly available in a clinic. The United 
Imaging FuncTool can rapidly analyze the single-
slice ADC map to produce a histographic display 
of voxel occurrence frequency as a function of 
ADC value, e.g., ADCpeak, ADClowest and the 
overall shape of the ADC histogram [18]. 
 
In this study, the changes in ADCpeak were more 
significant in the responder group than in the 
non-responder group, which had been previously 
reported for other tumors [9]. ADCpeak indicates 
that a larger proportion of the tumor, has the 
highest frequency, and tissues with high ADC 
values account for a significant part of the whole 
lesion. We speculated that if this part of the 
tumor greatly changed during the treatment, so 
would the value of the peak. Thus, ADCpeak may 
be a promising parameter to assess early 
treatment responses in lung cancer. 
 
The results demonstrated that ADClowest of the 
tumor increased after treatment, both in the 
responder group and non-responder group, and 
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that the changes in the responder group were 
larger, although not significant than in the non-
responder group. This result was not consistent 
with the results of previous research. Previous 
findings demonstrated that low percentile ADC 
values taken from the left leading edge of the 
tumor histogram increased more after treatment 
in the responder group than in the non-responder 
group [26]. We speculate that this was because 
the ADClowest was not stable and the number of 
pixels of ADClowest from the histogram was 
relatively small. Additionally, this value may be 
easily affected by noise, artifacts, and adjacent 
structures, which are difficult to avoid. In addition, 
some ROIs encompassed cavities found in the 
tumor or occurring after the biopsy, which would 
also affect the results (Figure 1). 
 
Besides various ADC values, the shape of the 
ADC histogram also indicated the character of 
the tissue structure. In addition, by using 
histogram analysis in pre- and post-treatment, 
the histogram could show changes in tumor 
heterogeneity. The histogram of the responder 
group shifted obviously to the right side (Figure 
2), indicating a larger proportion of tumors with a 
higher ADC value after treatment than pre-
chemotherapy. However, the histogram graph 
did not shift significantly to the right side in the 
non-responder group (Figure 3). In responder 
group, tumor cell necrosis resulted in increased 
ADC after therapy. This result is consistent with 
reports of other tumors in the literature [19,20]. 
The findings suggest that single-slice ADC 
histogram analysis is a rapid and clinically useful 
technique to monitor the early tumor response 
and predict the effectiveness of lung cancer 
therapy. 
 
The present study has some limitations. There 
were few patients were enrolled in this study. In 
future studies, the inclusion of more patients will 
help determine and validate the proper cutoff 
value for detecting responders in single-slice 
ADC histogram analysis. We used b values of 50 
and 800 in the diffusion MRI protocol, but other b 
values were not used. Thus, the best b value for 
lung imaging was not determined. It will be 
necessary to use other b values for DWI to 




Figure 1: Male patient, 66 years old, squamous cell 
carcinomas. ADC map (A) and T2-weighted axial 





Figure 2: Male patient, 76 years old, small cell 
carcinoma. Change in histogram between pre- and 
post-treatment chemotherapy in responder patient. 
ADC map (A, C) and single-slice histogram (B, D) 
show ADC value displayed on the x-axis with ADC in 
cm2/s × 10−2; the number of pixels is displayed on the 
y-axis. The histogram graph shifts visibly to the right 
side after two weeks of therapy. After 3 months of 
therapy, the largest diameter of target lesions 
decreased by at least 90 % (E) 
 
 
Figure 3: Male patient, 69 years old, squamous cell 
carcinomas. Change in histogram between pre- and 
post-treatment chemotherapy in non-responder 
patients. ADC map (A, C) and single-slice histogram 
(B, D) show the ADC value displayed on the x-axis 
with ADC in cm2/s × 10−2; the number of pixels is 
displayed on the y-axis. The histogram graph does not 
shift significantly to the right side after 2 weeks of 
therapy. After 3 months of therapy, there was 
approximately a 10% increase in the largest diameter 
of target lesion (E) 
 





ADC values obtained from single-slice histogram 
analysis of lung cancer may provide a useful tool 
for monitoring early tumor response and 
evaluating the effectiveness of a therapy. If this 
method is successfully used in practice, 
physicians would be able to reliably predict the 
early response to chemotherapy for lung cancer. 
Once the candidate drugs have been shown to 
be ineffective, patients could immediately try 
different anticancer drugs. This method will avoid 
situations where the toxic effects of anticancer 
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